Halozyme Therapeutics, Inc. $HALO Shares Sold by KBC Group NV

KBC Group NV lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 99.2% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,361 shares of the biopharmaceutical company’s stock after selling 402,284 shares during the period. KBC Group NV’s holdings in Halozyme Therapeutics were worth $175,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Wealth Preservation Advisors LLC purchased a new position in Halozyme Therapeutics in the first quarter valued at $32,000. SVB Wealth LLC acquired a new stake in Halozyme Therapeutics in the 1st quarter valued at about $33,000. Brooklyn Investment Group boosted its stake in shares of Halozyme Therapeutics by 1,558.1% in the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 670 shares during the period. CWM LLC grew its position in shares of Halozyme Therapeutics by 46.3% during the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock worth $88,000 after buying an additional 438 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Halozyme Therapeutics during the first quarter worth approximately $89,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $69.13, for a total transaction of $1,382,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at approximately $50,721,994.47. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Nicole Labrosse sold 2,227 shares of Halozyme Therapeutics stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $77.95, for a total transaction of $173,594.65. Following the completion of the transaction, the chief financial officer directly owned 22,079 shares in the company, valued at $1,721,058.05. The trade was a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 110,227 shares of company stock valued at $8,028,955. 2.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

HALO has been the subject of a number of recent research reports. JMP Securities lifted their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research note on Wednesday, August 6th. Zacks Research cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Weiss Ratings reissued a “buy (b)” rating on shares of Halozyme Therapeutics in a report on Thursday, November 13th. Leerink Partners raised Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target for the company in a report on Tuesday, October 14th. Finally, Citizens Jmp increased their price objective on Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $75.10.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $70.25 on Thursday. The company has a fifty day moving average of $69.93 and a two-hundred day moving average of $63.41. The company has a market capitalization of $8.26 billion, a PE ratio of 16.08, a P/E/G ratio of 0.35 and a beta of 1.18. Halozyme Therapeutics, Inc. has a 1 year low of $44.10 and a 1 year high of $79.50. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.09. The business had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business’s quarterly revenue was up 22.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.27 EPS. As a group, analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.